Literature DB >> 26009469

Locating Herpesvirus Bcl-2 Homologs in the Specificity Landscape of Anti-Apoptotic Bcl-2 Proteins.

Glenna Wink Foight1, Amy E Keating2.   

Abstract

Viral homologs of the anti-apoptotic Bcl-2 proteins are highly diverged from their mammalian counterparts, yet they perform overlapping functions by binding and inhibiting BH3 (Bcl-2 homology 3)-motif-containing proteins. We investigated the BH3 binding properties of the herpesvirus Bcl-2 homologs KSBcl-2, BHRF1, and M11, as they relate to those of the human Bcl-2 homologs Mcl-1, Bfl-1, Bcl-w, Bcl-xL, and Bcl-2. Analysis of the sequence and structure of the BH3 binding grooves showed that, despite low sequence identity, M11 has structural similarities to Bcl-xL, Bcl-2, and Bcl-w. BHRF1 and KSBcl-2 are more structurally similar to Mcl-1 than to the other human proteins. Binding to human BH3-like peptides showed that KSBcl-2 has similar specificity to Mcl-1, and BHRF1 has a restricted binding profile; M11 binding preferences are distinct from those of Bcl-xL, Bcl-2, and Bcl-w. Because KSBcl-2 and BHRF1 are from human herpesviruses associated with malignancies, we screened computationally designed BH3 peptide libraries using bacterial surface display to identify selective binders of KSBcl-2 or BHRF1. The resulting peptides bound to KSBcl-2 and BHRF1 in preference to Bfl-1, Bcl-w, Bcl-xL, and Bcl-2 but showed only modest specificity over Mcl-1. Rational mutagenesis increased specificity against Mcl-1, resulting in a peptide with a dissociation constant of 2.9nM for binding to KSBcl-2 and >1000-fold specificity over other Bcl-2 proteins, as well as a peptide with >70-fold specificity for BHRF1. In addition to providing new insights into viral Bcl-2 binding specificity, this study will inform future work analyzing the interaction properties of homologous binding domains and designing specific protein interaction partners.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BH3 peptides; BHRF1; KSBcl-2; bacterial surface display; peptide design

Mesh:

Substances:

Year:  2015        PMID: 26009469      PMCID: PMC4520770          DOI: 10.1016/j.jmb.2015.05.015

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  79 in total

1.  BH3 Profiling Reveals Selectivity by Herpesviruses for Specific Bcl-2 Proteins To Mediate Survival of Latently Infected Cells.

Authors:  Olesea Cojohari; Christine M Burrer; Megan A Peppenelli; Fardokht A Abulwerdi; Zaneta Nikolovska-Coleska; Gary C Chan
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

2.  Viral Bcl-2 Encoded by the Kaposi's Sarcoma-Associated Herpesvirus Is Vital for Virus Reactivation.

Authors:  Anastasia Gelgor; Inna Kalt; Shir Bergson; Kevin F Brulois; Jae U Jung; Ronit Sarid
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

3.  In silico and in vitro elucidation of BH3 binding specificity toward Bcl-2.

Authors:  Nir London; Stefano Gullá; Amy E Keating; Ora Schueler-Furman
Journal:  Biochemistry       Date:  2012-07-12       Impact factor: 3.162

4.  Predictive Bcl-2 family binding models rooted in experiment or structure.

Authors:  Joe DeBartolo; Sanjib Dutta; Lothar Reich; Amy E Keating
Journal:  J Mol Biol       Date:  2012-05-19       Impact factor: 5.469

5.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

6.  Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL.

Authors:  Sanjib Dutta; Jeremy Ryan; T Scott Chen; Christos Kougentakis; Anthony Letai; Amy E Keating
Journal:  J Mol Biol       Date:  2014-11-14       Impact factor: 5.469

7.  The functional differences between pro-survival and pro-apoptotic B cell lymphoma 2 (Bcl-2) proteins depend on structural differences in their Bcl-2 homology 3 (BH3) domains.

Authors:  Erinna F Lee; Grant Dewson; Marco Evangelista; Anne Pettikiriarachchi; Grace J Gold; Haoran Zhu; Peter M Colman; W Douglas Fairlie
Journal:  J Biol Chem       Date:  2014-11-03       Impact factor: 5.157

8.  Structure-based redesign of the binding specificity of anti-apoptotic Bcl-x(L).

Authors:  T Scott Chen; Hector Palacios; Amy E Keating
Journal:  J Mol Biol       Date:  2012-11-12       Impact factor: 5.469

9.  Peptide ligands for pro-survival protein Bfl-1 from computationally guided library screening.

Authors:  Sanjib Dutta; T Scott Chen; Amy E Keating
Journal:  ACS Chem Biol       Date:  2013-02-21       Impact factor: 5.100

10.  The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist.

Authors:  G J P Rautureau; M Yabal; H Yang; D C S Huang; M Kvansakul; M G Hinds
Journal:  Cell Death Dis       Date:  2012-12-13       Impact factor: 8.469

View more
  10 in total

1.  Comparison of the peptide binding preferences of three closely related TRAF paralogs: TRAF2, TRAF3, and TRAF5.

Authors:  Glenna Wink Foight; Amy E Keating
Journal:  Protein Sci       Date:  2016-02-03       Impact factor: 6.725

2.  [Effects of simvastatin on aortic vascular endothelial cell apoptosis and Bcl-2 protein expression in a rat model of atherosclerosis].

Authors:  Si-Gan Hu; Hui Li; Pin-Fang Kang; Tian-Ping Chen; Miao-Nan Li; Jian Zhu; Da-Sheng Gao; Heng Zhang; Hong-Ju Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-11-20

3.  Peptide design by optimization on a data-parameterized protein interaction landscape.

Authors:  Justin M Jenson; Vincent Xue; Lindsey Stretz; Tirtha Mandal; Lothar Luther Reich; Amy E Keating
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-15       Impact factor: 11.205

4.  Enriching Peptide Libraries for Binding Affinity and Specificity Through Computationally Directed Library Design.

Authors:  Glenna Wink Foight; T Scott Chen; Daniel Richman; Amy E Keating
Journal:  Methods Mol Biol       Date:  2017

Review 5.  Designing helical peptide inhibitors of protein-protein interactions.

Authors:  Raheleh Rezaei Araghi; Amy E Keating
Journal:  Curr Opin Struct Biol       Date:  2016-04-25       Impact factor: 6.809

6.  Selective peptide inhibitors of antiapoptotic cellular and viral Bcl-2 proteins lead to cytochrome c release during latent Kaposi's sarcoma-associated herpesvirus infection.

Authors:  Christine M Burrer; Glenna W Foight; Amy E Keating; Gary C Chan
Journal:  Virus Res       Date:  2015-10-09       Impact factor: 3.303

Review 7.  EBV and Apoptosis: The Viral Master Regulator of Cell Fate?

Authors:  Leah Fitzsimmons; Gemma L Kelly
Journal:  Viruses       Date:  2017-11-13       Impact factor: 5.048

8.  Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1.

Authors:  Justin M Jenson; Jeremy A Ryan; Robert A Grant; Anthony Letai; Amy E Keating
Journal:  Elife       Date:  2017-06-08       Impact factor: 8.140

9.  Expression of tissue inhibitor of metalloproteinases-1 and B-cell lymphoma-2 in the synovial membrane in patients with knee osteoarthritis.

Authors:  Xiaomiao Li; Xiaodong Fu; Yingjian Gao; Hao Li; Weili Wang; Yi Shen
Journal:  Exp Ther Med       Date:  2017-11-08       Impact factor: 2.447

10.  Transient Unfolding and Long-Range Interactions in Viral BCL2 M11 Enable Binding to the BECN1 BH3 Domain.

Authors:  Arvind Ramanathan; Akash Parvatikar; Srinivas C Chennubhotla; Yang Mei; Sangita C Sinha
Journal:  Biomolecules       Date:  2020-09-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.